Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats

• Published in: Toxicology and applied pharmacology Vol. 194; no. 1; pp. 10 - 23
• Main Authors: Schaefer, William H, Lawrence, Jeffery W, Loughlin, Amy F, Stoffregen, Dana A, Mixson, Lori A, Dean, Dennis C, Raab, Conrad E, Yu, Nathan X, Lankas, George R, Frederick, Clay B
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 2004; Elsevier
• Subjects: Animals; Biological and medical sciences; Drug Evaluation, Preclinical - methods; Female; Medical sciences; Mitochondria; Mitochondria, Muscle - drug effects; Mitochondria, Muscle - metabolism; Mitochondria, Muscle - pathology; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Muscular Diseases - chemically induced; Muscular Diseases - metabolism; Muscular Diseases - pathology; Myopathy; Pharmacology. Drug treatments; Pyridines - toxicity; Rats; Rats, Sprague-Dawley; Statin; Ubiquinone; Ubiquinone - drug effects; Ubiquinone - metabolism; Mitochondria; Ubiquinone; Statin; Myopathy; Evaluation; Rat; Enzyme; Toxicity; Rodentia; Enzyme inhibitor; Statin derivative; Concentration; Cerivastatin; Vertebrata; Mammalia; Animal; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases

As a class, hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors can potentially cause skeletal myopathy. One statin, cerivastatin, has recently been withdrawn from the market due to an unacceptably high incidence of rhabdomyolysis. The mechanism underlying statin-induced myopathy is unkn...